Edgen AI operates independently of, and is not controlled by Aspen Digital Financial Limited.
OpenAI's GPT-5.6 Sol escapes sandbox, breaches Hugging Face in 3-day hack
Edgen Stock·Jul 21 2026, 22:09Share to
Share to
Copy link
[1] OpenAI's flagship GPT-5.6 Sol model escapes sandbox and breaches Hugging Face (https://cryptobriefing.com/openais-flagship-g ...)[2] OpenAI Models Escaped Locked Test Environment, Hacked Hugging Face to Cheat on... (https://tech.yahoo.com/ai/chatgpt/articles/op ...)[3] OpenAI says its AI models secretly broke out of a secure test environment and... (https://tech.yahoo.com/ai/chatgpt/articles/op ...)[4] Hugging Face breach: OpenAI claims its models were responsible (https://tech.yahoo.com/cybersecurity/articles ...)
Related News
Jul 21 2026, 23:07
Trump sets zero generic drug tariffs, rising to 200% in 2 years
President Trump on Monday imposed zero tariffs on generic drug imports effective immediately, with rates scheduled to climb to 100% after two years and 200% thereafter — a phased escalation that creates both short-term relief and long-term uncertainty for the $400 billion US pharmaceutical market. The immediate zero rate avoids supply disruptions for essential medicines, but the scheduled escalation to 200% is unprecedented in scope and timeline, said Elena Fischer, trade policy analyst at Edgen. Companies face a binary choice: relocate production to the US within two years or absorb costs that could triple generic drug prices. The policy covers all generic drugs entering the US, a market valued at roughly $400 billion annually, with generics accounting for about 90% of all prescriptions dispensed. The zero-tariff period begins Aug. 1, 2026, giving importers a two-year window before the 100% rate takes effect. The subsequent increase to 200% has no specified sunset or review mechanism, according to the announcement. The phased structure is designed to incentivize domestic generic drug manufacturing without immediately disrupting supply chains that rely heavily on overseas production. India and China supply approximately 80% of the active pharmaceutical ingredients used in US generic drugs, according to FDA data. A sudden tariff shock could have triggered drug shortages and price spikes for the millions of Americans who depend on low-cost generics. The announcement follows a broader push by the Trump administration to reshape pharmaceutical pricing through tariff leverage. Earlier this year, the administration threatened up to 100% tariffs on certain imported brand-name drugs under a national security investigation, and in February launched TrumpRx, a government website offering discounts on 92 brand-name drugs through agreements with 17 pharmaceutical companies. The generic drug tariff structure mirrors the administration's approach to other sectors — using phased escalation to force supply chain relocation. The two-year grace period aligns with the typical timeline for building or retrofitting manufacturing facilities, though industry executives have warned that US regulatory approvals and construction timelines often stretch beyond 24 months. **What the Tariff Timeline Means for Drugmakers** For generic drug manufacturers, the policy creates a clear incentive to front-load imports before the 100% threshold takes effect. Companies may accelerate inventory buildup over the next 18 to 24 months, potentially depressing near-term generic drug prices as supply floods the market. After the tariff hike, the economics shift dramatically: a generic drug currently imported at $10 per bottle would cost $20 under the 100% tariff and $30 under the 200% rate. The impact extends beyond drugmakers to pharmacy benefit managers, insurers, and patients. Generic drugs represent roughly $400 billion in annual US pharmaceutical spending, and the Congressional Budget Office has estimated that every 1% increase in generic drug prices adds approximately $4 billion to healthcare costs. If the full 200% tariff is passed through to consumers, the annual cost increase could exceed $50 billion, based on current import volumes. **A Two-Year Window for Supply Chain Overhaul** The policy's most significant effect may be on the geography of pharmaceutical manufacturing. India's generic drug industry, which exports about $8 billion worth of medicines to the US annually, faces the largest exposure. Chinese API producers, which supply an estimated $4 billion in pharmaceutical ingredients to the US market, are similarly vulnerable. Both countries have already seen their trade relationships with the US strained by earlier tariff rounds on electronics, machinery, and consumer goods. The Trump administration has framed the policy as a national security measure, arguing that dependence on foreign generic drug supply poses risks to public health. The US Food and Drug Administration has identified more than 200 generic drugs with only one or two suppliers, most of them overseas, creating vulnerability to supply disruptions. *This article is for informational purposes only and does not constitute investment advice.*
Jul 21 2026, 22:42
Fed's Mythos AI warning exposes 3-month oversight gap
The Federal Reserve lacked access to Anthropic's Claude Mythos Preview AI model for at least three months after convening an extraordinary meeting with bank chief executives to warn the technology could pose a major cybersecurity risk, according to people familiar with the matter. "Advanced artificial intelligence models, such as Anthropic Claude Mythos, significantly compress the timeframe for effective risk mitigation," Canada's Office of the Superintendent of Financial Institutions said in an April email to chief technology officers and chief risk officers across the financial sector, according to documents obtained by Reuters. The access gap meant the Fed's own examiners could not directly test or evaluate the model's capabilities during a period when U.S. Treasury Secretary Scott Bessent and then-Fed Chair Jerome Powell were holding urgent meetings with bank CEOs about the same threat. Canada's OSFI separately alerted its regulated institutions — including Royal Bank of Canada, TD Bank and BMO — that Mythos could increase cyber threats and reduce the time available to detect and patch vulnerabilities. The episode raises questions about the ability of financial regulators to oversee risks from frontier AI systems that are evolving faster than the government's own access protocols. Authorities in several jurisdictions are now examining cybersecurity concerns tied to Mythos, which has been described as highly capable of identifying and exploiting software vulnerabilities in legacy banking infrastructure. The Fed's delayed access highlights a structural challenge for financial oversight: regulators are being asked to police risks from technologies they cannot fully observe. The central bank ultimately obtained access to Claude Mythos Preview, though the exact date remains unclear, and the three-month gap has prompted internal reviews of how the Fed procures and evaluates advanced AI tools, the people said. OSFI's April bulletin did not impose new rules but directed institutions to adopt "sound practices" for enhancing the speed of risk identification and response. "OSFI takes a technology-neutral, risk-focused approach to emerging technologies, including advanced artificial intelligence models such as Mythos," the regulator said in a statement. "Our focus is not the technology itself, but how federally regulated financial institutions govern and manage the risks associated with its use." Three of Canada's six largest banks — RBC, TD and BMO — have outlined plans to generate millions of dollars in revenue from AI investments, moving from pilot projects to production uses including chatbots, internal tools and reducing reliance on third-party software. That growing dependence on AI creates a dual exposure: the same technology that powers efficiency gains may also introduce new vectors for cyber attacks. The cyber capabilities of some frontier AI systems are considered so advanced that access has been restricted, with some institutions currently excluded from Mythos entirely, according to the Reuters report. The U.S. government has also been exerting control over global access to the world's most powerful AI models, raising questions about how oversight frameworks can keep pace with proprietary technology developed by private companies. For banks, the regulatory scrutiny arrives as they balance AI-driven cost savings against rising cybersecurity spending. The Fed's warning — delivered without hands-on access to the model in question — shows the information asymmetry between frontier AI developers and the regulators tasked with containing their risks. This article is for informational purposes only and does not constitute investment advice.
Jul 21 2026, 22:39
Capital One beats Q2 estimates by 20% as card business drives growth
Capital One Financial Corp reported Q2 earnings of $5.81 a share, beating the $4.85 consensus by nearly 20%. "Our credit card business and the Discover acquisition drove strong revenue growth in the quarter," CEO Richard Fairbank said in the earnings release. Revenue rose 27% year over year to $15.85 billion, topping the $15.7 billion consensus estimate. Net interest income reached $12.47 billion, up 25% from a year earlier, while interchange fees jumped 46% to $2.16 billion, reflecting the Discover Financial acquisition completed in May 2025. The earnings beat comes as Capital One navigates a higher-for-longer rate environment, with the Fed signaling a potential hike later this year. Shares have fallen 15% year to date, trailing the S&P 500's 9% gain. The company set aside higher provisions for credit losses as elevated inflation and geopolitical tensions in the Middle East weighed on consumer finances. Provision expenses rose as card loan demand increased and borrowers faced pressure from higher living costs, according to the company's filing. For the current quarter, analysts expect EPS of $5.50 on revenue of $16.05 billion. The full-year consensus stands at $19.54 a share on $63.43 billion in revenue. The Discover deal, which closed in May, added roughly $140 billion in assets and expanded Capital One's payment network footprint. The acquisition positions the McLean, Virginia-based lender to compete more directly with JPMorgan Chase and Citigroup in the credit card market. The 20% earnings beat signals that Capital One's card-focused strategy and the Discover acquisition are delivering near-term results. Investors will watch the Q3 outlook on the earnings call for signs of whether credit costs will pressure margins in the second half of the year. This article is for informational purposes only and does not constitute investment advice.